STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Immunocore Holdings plc American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Filing: Schedule 13G/A (Amendment No. 5) reporting for Immunocore Holdings plc (CUSIP 45258D105).

Key facts: Wellington Management Group LLP and affiliated entities report beneficial ownership of 5,132,898 shares of Immunocore common stock (reported as 10.2% / 10.22% of the class). Reported ownership shows no sole voting or dispositive power; shared voting power is reported as 4,958,998 and shared dispositive power as 5,132,898. The filing notes these shares are owned of record by clients of Wellington investment advisers and identifies Vanguard Health Care Fund as an exception referenced in Item 6. The issuer address and filer addresses are included; the filing is signed by Taisia Lowe on 08/05/2025.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Wellington discloses a material >5% position in IMCR (5.13M shares, ~10.2%), disclosed as shared voting/dispositive power.

The Schedule 13G/A shows Wellington and affiliated entities collectively beneficially own 5,132,898 Immunocore shares, representing roughly 10.2% of the class. Ownership is reported as held in the ordinary course for clients of Wellington investment advisers, with no sole voting or dispositive power reported and shared voting power of 4,958,998. This is a routine institutional disclosure for a substantial passive stake; it signals concentration of shareholder exposure but does not, on its face, indicate an intent to influence control per the filer’s certification.

TL;DR: Material passive stake disclosed; structure shows shared control across Wellington entities, with formal certification of non-control intent.

The filing identifies multiple Wellington entities (HC and IA classifications) and documents the ownership chain and adviser relationships. The certification states holdings are "in the ordinary course of business" and not held to change or influence control. For governance monitoring, the >5% disclosure is material for investor relations and proxy considerations, but the filing asserts passive intent and reports no sole voting or dispositive authority.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/05/2025
Immunocore Holdings Plc

NASDAQ:IMCR

IMCR Rankings

IMCR Latest News

IMCR Latest SEC Filings

IMCR Stock Data

1.79B
49.40M
5.08%
98.18%
17.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United Kingdom
OXFORDSHIRE